Cbd Group
Tosha Dickason
The Group call enables you to identify what account or organization your users are part of. There are two IDs that are relevant in a Group call: the userId, which belongs and refers to the user, and the groupId, which belongs and refers to the specific group. A user can be in more than one group which would mean different groupIds, but the user will only have one userId that is associated to each of the different groups. Keep in mind that not all platforms support multiple groups for a single user.
Note: In our browser and mobile libraries a User ID is automatically added from the state stored by a previous identify call, so you do not need to add it yourself. They will also automatically handle Anonymous IDs under the covers.
If you pass these values, on null will throw a NullPointerException.You may continue to set values inside the trait. If you do so, this would work the same as the rules do with NoSQL data. If you had set a value previously for a user and on the next request you sent the same value of that property as on null, it will be replaced by null, but if you do not send that property, the original value is persisted.
Traits are case-insensitive, so in JavaScript you can match the rest of your camel-case code by sending createdAt, and in Ruby you can match your snake-case code by sending created_at. That way the API never seems alien to your code base.
The console.group() static method creates a new inline group in the Web console log, causing any subsequent console messages to be indented by an additional level, until console.groupEnd() is called.
You can use nested groups to help organize your output by visually associating related messages. To create a new nested block, call console.group(). The console.groupCollapsed() method is similar, but the new block is collapsed and requires clicking a disclosure button to read it.
The National Multi-Agency Coordinating Group (NMAC) is comprised of members who have been delegated authority to provide an essential management mechanism for national level strategic coordination to ensure that firefighting resources are efficiently and appropriately managed in a cost-effective manner. Their mission is to provide national wildland fire operations management, priority setting, and resource allocation through multi-agency coordination. The group is represented by leadership from the following agencies:
The National Interagency Fire Center is committed to making its information and communication technologies accessible to individuals with disabilities by meeting or exceeding the requirements of Section 508 of the Rehabilitation Act of 1973, as amended. To meet this commitment, we continue to monitor and update our content to make sure our documents meet these standards.
This edition of Forum examines the economic and mental health effects of living in the same household as a person with depressive symptoms, as well as the use of financial innovation to meet emission reduction goals.
Professor Wei is the scientific director for the program of quantitative science in pharmaceutical medicine at the Harvard T.H. Chan School of Public Health. He is an expert in biostatistics and in the development of statistical methods for the design and analysis of clinical trials, and has provided deposition and trial testimony in numerous matters regarding the effectiveness of various therapies. Professor Wei also has served as an expert and advisor to a number of pharmaceutical companies and regulatory agencies, including the US Food and Drug Administration (FDA), and has served on a number of FDA and National Institutes of Health committees.
Professor Wei has developed numerous statistical methods that are utilized extensively in practice. He has concentrated his recent research on the development of personalized medicine strategies for diagnostics and treatment selection, and has been intimately involved in advising the pharmaceutical industry on new drug applications.
The author of more than 140 articles in statistical and medical journals, Professor Wei has served on the editorial boards of the Journal of the American Statistical Association and the Journal of Biopharmaceutical Statistics. He is an elected fellow of the Institute of Mathematical Statistics and the American Statistical Association, which honored him with the Mosteller Statistician of the Year award in 2007.
For more than 25 years, Mr. Christensen has worked on high-stakes litigation matters with world-class experts, supporting their testimony at both bench and jury trials. His work has focused on valuation and appraisal matters, private equity disputes, antitrust and consent decree litigations, bankruptcy, and tax and transfer pricing dispute resolutions. Through his extensive experience, he has developed a deep understanding of the high-tech, digital advertising, pharmaceutical, media and entertainment, and finance industries. In addition to his litigation work, Mr. Christensen has also assisted in the preparation of numerous impact studies in the high-tech space on issues such as cloud computing and storage, broadband availability, virtual and augmented reality, artificial intelligence, and the metaverse. His clients have included Meta/Facebook, Google, GSK, AstraZeneca, JAB Holding Company, Bank of America, BNP, and Fidelity. Among his engagements are high-tech antitrust matters, a GSK transfer pricing dispute, the Nortel Networks bankruptcy, Delaware appraisal trial victories involving PetSmart and Panera, and rate-setting trials for BMI. Mr. Christensen is a CFA charterholder.
Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation, damages, and valuation in a variety of health care cases, including cases involving allegations of False Claims Act (FCA), Anti-Kickback Statute (AKS), and Lanham Act violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.
Mr. Gissiner has more than four decades of diversified experience in the retirement plan industry. He is an expert in retirement plan design, compliance, administrative procedures, employee communications and investment education services, and fiduciary responsibility and oversight. Mr. Gissiner has consulted on these and other topics to hundreds of retirement plan sponsors over the course of his career, including various Fortune 500 companies, mutual fund and insurance companies, banks, health care providers, and institutions of higher learning. In addition, he has served as an expert witness in various litigation matters involving defined-contribution retirement plans.
At Orchard Hills Consulting, Mr. Gissiner currently consults on behalf of a number of clients on a wide range of retirement plain issues including (but not limited to) retirement plan administration and compliance consulting, fee benchmarking, assisting plan sponsors and committees in understanding and implementing administrative and recordkeeping fee arrangements, developing service provider requests for proposals, and reviewing modifications to existing plan features and provisions. Earlier in his career, he was a partner in the benefits consulting practice of Coopers & Lybrand. Later, he served as the West Region Managing Partner for retirement plan administrative outsourcing services at PriceWaterhouseCoopers.
Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and government investigations in the areas of antitrust and competition, labor and employment, health care, and commercial damages. She has evaluated market definition, market power, competitive dynamics, class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In her work with pharmaceutical and medical device industries, she has analyzed economic, health, and scientific data to assess liability, damages, and claims of causation and harm. She also frequently supports biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, medical claims, and adverse events data in product liability litigations and intellectual property disputes. She has authored expert reports and provided testimony in competition, data security breach, labor and employment, and commercial litigation matters.
c80f0f1006